ABT-558
ABT-558
ABT-558 is a synthetic peptide that functions as an angiogenesis inhibitor. It is primarily studied for its potential therapeutic applications in cancer treatment, where it aims to prevent the growth of new blood vessels that tumors need to grow and metastasize. This article provides a comprehensive overview of ABT-558, including its mechanism of action, clinical applications, and research status.
Mechanism of Action[edit | edit source]
ABT-558 is designed to inhibit angiogenesis, the process by which new blood vessels form from pre-existing vessels. This process is crucial for tumor growth and metastasis, as tumors require a blood supply to receive nutrients and oxygen. ABT-558 works by targeting specific pathways involved in angiogenesis, thereby preventing the formation of new blood vessels.
Target Pathways[edit | edit source]
ABT-558 primarily targets the vascular endothelial growth factor (VEGF) pathway, which is a key regulator of angiogenesis. By inhibiting VEGF, ABT-558 reduces the proliferation and migration of endothelial cells, which are essential for new blood vessel formation.
Clinical Applications[edit | edit source]
The primary clinical application of ABT-558 is in the treatment of various types of cancer. By inhibiting angiogenesis, ABT-558 aims to starve tumors of their blood supply, thereby inhibiting their growth and ability to spread.
Cancer Types[edit | edit source]
Research has focused on the use of ABT-558 in several cancer types, including:
Research and Development[edit | edit source]
ABT-558 is currently in the experimental stages of development. Preclinical studies have shown promising results in animal models, demonstrating its ability to inhibit tumor growth. However, further research is needed to determine its efficacy and safety in humans.
Clinical Trials[edit | edit source]
As of the latest updates, ABT-558 is undergoing early-phase clinical trials to evaluate its safety, tolerability, and preliminary efficacy in patients with advanced solid tumors.
Potential Side Effects[edit | edit source]
As with other angiogenesis inhibitors, potential side effects of ABT-558 may include:
- Hypertension
- Fatigue
- Gastrointestinal disturbances
- Hemorrhage
Also see[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
